Abstract
Cysteinlyl-leukotriene receptor antagonists (LTRAs) were introduced as oral preventative antiasthma medications in the late 1990s and, very recently, montelukast has been approved also for the relief of symptoms of perennial and seasonal allergic rhinitis. Although clinical trials and clinical practice showed LTRAs to be effective in the treatment of asthma patients with a wide range of disease severity, their exact role in the therapy of asthma is not well defined and possibly under-appreciated. As for other anti-asthma drugs, clinical trials with LTRAs uncovered a range of patient responses, so that an understanding of the variability mechanisms (e.g. acquired or genetic factors, etc.) is needed to maximize the probability of a beneficial response. Since the molecular cloning of CysLT receptors (CysLTRs) has been achieved, new roles for cysteinyl-LTs in pathophysiological conditions have been suggested or established from the observed distribution in cells and tissues other than the lung. Cysteinyl-LTs and CysLTRs have been implicated in the pathophysiology of other inflammatory conditions including cancer, atopic dermatitis, idiopathic chronic urticaria, and cardiovascular diseases. As a result, LTRAs might be worth assessing for a therapeutic role in some of these pathologies. This review summarizes and attempts to integrate recent data on the therapeutic efficacy, effectiveness and safety of LTRAs in asthma and allergic rhinitis, and speculates on other therapeutic opportunities.
Keywords: Cysteinyl-leukotrienes, CysLT receptors, Leukotriene receptor antagonists, Asthma, Allergic rhinitis, Montelukast, Zafirlukast, Pranlukast
Current Medicinal Chemistry
Title: Cysteinyl-Leukotriene Receptor Antagonists: Present Situation and Future Opportunities
Volume: 13 Issue: 26
Author(s): V. Capra, M. Ambrosio, G. Riccioni and G. E. Rovati
Affiliation:
Keywords: Cysteinyl-leukotrienes, CysLT receptors, Leukotriene receptor antagonists, Asthma, Allergic rhinitis, Montelukast, Zafirlukast, Pranlukast
Abstract: Cysteinlyl-leukotriene receptor antagonists (LTRAs) were introduced as oral preventative antiasthma medications in the late 1990s and, very recently, montelukast has been approved also for the relief of symptoms of perennial and seasonal allergic rhinitis. Although clinical trials and clinical practice showed LTRAs to be effective in the treatment of asthma patients with a wide range of disease severity, their exact role in the therapy of asthma is not well defined and possibly under-appreciated. As for other anti-asthma drugs, clinical trials with LTRAs uncovered a range of patient responses, so that an understanding of the variability mechanisms (e.g. acquired or genetic factors, etc.) is needed to maximize the probability of a beneficial response. Since the molecular cloning of CysLT receptors (CysLTRs) has been achieved, new roles for cysteinyl-LTs in pathophysiological conditions have been suggested or established from the observed distribution in cells and tissues other than the lung. Cysteinyl-LTs and CysLTRs have been implicated in the pathophysiology of other inflammatory conditions including cancer, atopic dermatitis, idiopathic chronic urticaria, and cardiovascular diseases. As a result, LTRAs might be worth assessing for a therapeutic role in some of these pathologies. This review summarizes and attempts to integrate recent data on the therapeutic efficacy, effectiveness and safety of LTRAs in asthma and allergic rhinitis, and speculates on other therapeutic opportunities.
Export Options
About this article
Cite this article as:
Capra V., Ambrosio M., Riccioni G. and Rovati E. G., Cysteinyl-Leukotriene Receptor Antagonists: Present Situation and Future Opportunities, Current Medicinal Chemistry 2006; 13 (26) . https://dx.doi.org/10.2174/092986706778742963
DOI https://dx.doi.org/10.2174/092986706778742963 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
State of the Art and Perspectives in Food Allergy (Part II): Therapy
Current Pharmaceutical Design Radical-Scavenging Activity, Cytotoxicity and Chemical Constituents of Euphorbia orthoclada from Madagascar
The Natural Products Journal Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Inflammation, Oxidative Stress and Metabolic Syndrome: Dietary Modulation
Current Vascular Pharmacology Vitamin D in COPD - A Pleiotropic Micronutrient in a Multisystem Disease
Current Respiratory Medicine Reviews Anti-Inflammatory Iridoids of Botanical Origin
Current Medicinal Chemistry The Pharmacogenomics of Asthma Beyond its Endotypes
Current Drug Metabolism Non-IgE Mediated Food Allergy
Inflammation & Allergy - Drug Targets (Discontinued) Quantitative Structure Activity Relationship and Design of Phenyl Alkyl Ketone Derivatives as Inhibitors of Phosphodiesterase 4
Current Enzyme Inhibition Metabolism-based Drug-drug Interactions in Patients with Chronic Respiratory Diseases: A Review Focusing on Drugs Affecting the Respiratory System
Current Drug Metabolism Mechanical Ventilation Following Cardiac Surgery in Children
Current Respiratory Medicine Reviews Management Options in Childhood Asthma – What is the Current Evidence on which Treatment is Based?
Current Pediatric Reviews ACE Inhibition of Plant Alkaloids Targeted Approach for Selective Inhibition
Mini-Reviews in Organic Chemistry Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery The Immunomodulating Activities of Resveratrol Glucosides in Humans
Recent Patents on Food, Nutrition & Agriculture Edible Transgenic Plant Vaccines for Different Diseases
Current Pharmaceutical Biotechnology Cognitive - Behavioral Therapy in Central Sensitivity Syndromes
Current Rheumatology Reviews Application of In Vivo Animal Models to Characterize the Pharmacokinetic and Pharmacodynamic Properties of Drug Candidates in Discovery Settings
Combinatorial Chemistry & High Throughput Screening Is Ecto-nucleoside Triphosphate Diphosphohydrolase (NTPDase)-based Therapy of Central Nervous System Disorders Possible?
Mini-Reviews in Medicinal Chemistry The Effects of Olprinone, a Phosphodiesterase 3 Inhibitor, on Systemic and Cerebral Circulation
Current Vascular Pharmacology